Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

BACKGROUND: PD-1/PD-L1 blockade can confer durable benefits in the treatment of metastatic cancers, but the response rate remains modest and potential adverse effects occur sometimes. Concentrating immunotherapeutic agents at the site of disease was believed to break local immune tolerance and reduc...

Full description

Saved in:
Bibliographic Details
Published in:J Hematol Oncol
Main Authors: Yang, Yuanyuan, Zhang, Xiaolong, Lin, Fangzhen, Xiong, Mengshang, Fan, Dongmei, Yuan, Xiangfei, Lu, Yang, Song, Yuewen, Zhang, Yizi, Hao, Mu, Ye, Zhou, Zhang, Yanjun, Wang, Jianxiang, Xiong, Dongsheng
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6482514/
https://ncbi.nlm.nih.gov/pubmed/31023384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0723-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items